Prevalence of HPV infection and subtypes among male population in Qujing,Yunnan Province from 2017 to 2022
OBJECTIVE To investigate the prevalence of human papillomavirus(HPV)infection and genotypes of HPV among the male population in Qujing,Yunnan Province so as to provide bases for treatment of the male with HPV infection,selection and development of vaccine and decision of policies for immunization program.METHODS Totally 1 820 male patients who received HPV genotyping in the First People's Hospital of Qujing City from Jan 2017 to Dec 2022 were enrolled in the study,and the prevalence of HPV infection and genotypes a-mong the male patients were analyzed based on the genotyping result.RESULTS Totally 935 patients were tested positive for HPV infection among the 1820 patients,with the total infection rate 51.37％.The patients with sin-gle,double,triple and quadruple or above HPV genotypes infection accounted for 37.53％,9.62％,2.38％and 1.65％,respectively.Among the 27 genotypes tested,HPV6,HPV11,HPV43,HPV61 and HPV55 ranked the top 5 low-risk HPV genotypes,the positive rates were 25.93％,20.88％,1.92％,1.65％and 1.10％,respec-tively;HPV16,HPV59,HPV52,HPV18 and HPV58 ranked the top 5 high-risk genotypes,and the positive rates were 2.58％,2.09％,1.59％,1.48％and 1.48％,respectively.In general,the proportion of pure LR-HPV,pure HR-HPV and mixed infections were 74.33％,6.74％and 18.93％,respectively.The age specificity of the male population with infection showed a bimodal'U'distribution.CONCLUSION The HPV6,HPV11,HPV43,HPV16 and HPV59 are the most common genotypes among the male population with HPV infection in Qujing area.The infection rates were the highest among the patients with more than 59 years of age and the patients no more than 19 years of age.The population is generally characterized with high infection rate and tends to have multiple infec-tions,and it is dominated by the low-risk HPV infection,and the coverage rate of bivalent vaccine is low.
Human papillomavirusMaleCondyloma acuminataGenotypeQujing areaEpidemiologyHuman papil-lomavirus vaccine
NETL
NSTL
万方数据
